Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Income towards Parent Company (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Income towards Parent Company for 11 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Income towards Parent Company rose 13.41% to -$2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.4 million, a 881.67% decrease, with the full-year FY2024 number at -$10.7 million, down 284.73% from a year prior.
  • Income towards Parent Company was -$2.0 million for Q3 2025 at Marker Therapeutics, up from -$4.1 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $8.7 million in Q4 2023 to a low of -$10.9 million in Q2 2021.
  • A 5-year average of -$3.6 million and a median of -$2.4 million in 2024 define the central range for Income towards Parent Company.
  • Biggest YoY gain for Income towards Parent Company was 1173.9% in 2023; the steepest drop was 637.25% in 2023.
  • Marker Therapeutics' Income towards Parent Company stood at -$9.8 million in 2021, then soared by 91.67% to -$813063.0 in 2022, then surged by 1173.9% to $8.7 million in 2023, then crashed by 143.38% to -$3.8 million in 2024, then soared by 47.23% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Income towards Parent Company are -$2.0 million (Q3 2025), -$4.1 million (Q2 2025), and -$4.4 million (Q1 2025).